Comparison of Outcomes in Patients With Atrial Fibrillation Under Oral Anticoagulation Therapy Analyzed by Body Weight (<60, 60 to 100, and >100 kg)
Section snippets
Methods
A retrospective registry-based cohort study including all consecutive patients (n = 16,202) with a diagnosis of atrial fibrillation (AF) between January 2014 and January 2018 in the health area of Vigo (Galicia, Spain) was used (CardioCHUVI‐AF registry; ClinicalTrials.gov identifier: NCT04364516). Patients were identified through administrative databases and regional electronic medical records systems at both the hospital and outpatient levels. Clinical, laboratory, and therapeutic data were
Results
A total of 11,821 patients with AF under anticoagulation were included for statistical analysis, 924 with LBW, 9,393 with MBW, and 958 with HBW. Baseline characteristics of the total cohort according to the group of body weight are summarized in Table 1. The mean age was 77.2±8.9 years and approximately 52% of the participants were female. Most of the patients were treated with VKA (85%) and a few with DOACs (14%).
Regarding the characteristics of weight groups, patients with HBW had a higher
Discussion
We evaluated a large registry of more than 11,000 patients with AF under anticoagulant treatment with VKAs and with DOACs. After analyzing the events according to the weight group, the main findings are: (1) In the univariate analysis, the LBW group compared with the MBW group presented a higher risk of embolic events, mortality, and combined event. In contrast, HBW patients presented less risk. (2) In the multivariable analysis, no significant differences were found depending on the weight
Disclosures
The authors have no conflicts of interest to declare.
References (24)
- et al.
Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise
J Am Coll Cardiol
(2017) - et al.
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
J Thromb Haemost
(2016) - et al.
Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on T and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
J Thromb Haemost
(2005) - et al.
Non-vitamin K antagonist oral anticoagulant for atrial fibrillation in obese patients
Am J Cardiol
(2020) - et al.
Impact of body mass index on outcomes in the edoxaban versus warfarin therapy groups in patients underwent cardioversion of atrial fibrillation (from ENSURE-AF)
Am J Cardiol
(2019) - et al.
Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants
Heart Rhythm
(2017) - et al.
The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE)
J Thromb Haemost
(2005) - et al.
Relation of body mass index with adverse outcomes among patients with atrial fibrillation: a meta-analysis and systematic review
J Am Heart Assoc
(2016) - et al.
Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials
Stroke
(2017) - et al.
Heidbüchel H; External reviewers. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Europace
(2021)
The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review
Clin Res Cardiol
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Eur Heart J
Cited by (0)
Daiichi Sankyo (Madrid, Spain), Bayer (Barcelona, Spain), Boehringer Ingelheim (Barcelona, Spain), and Pfizer (Madrid, Spain), have provided unconditional financial support for this study.